Oxytocin’s Complicated Relationship With Erectile Dysfunction: Does It Really Make a Difference?

Everyone’s talking about oxytocin for erectile dysfunction. The so-called “love hormone” sounds appealing on paper: a natural peptide long associated with bonding, trust, and intimacy. BlueChew, a major ED telehealth provider, markets BlueChew Gold, a 4-in-1 formula that includes oxytocin alongside sildenafil, tadalafil, and apomorphine. Their marketing claims oxytocin “promotes bonding, trust, and emotional safety.” But when you examine the clinical evidence and basic pharmacology, a more complicated picture emerges.

As a registered nurse and writer who’s spent years reviewing clinical research for articles, I’ve learned to separate compelling narratives from actual evidence. The oxytocin story reveals two critical problems that deserve examination.

First, decades of promising animal research simply haven’t translated to human success—a fact that appears even in studies cited to support oxytocin’s inclusion in ED formulations. Second, and perhaps most importantly, sublingual oxytocin faces a fundamental absorption problem that makes effective dosing nearly impossible. Understanding these issues matters whether you’re considering BlueChew Gold or comparing it to established formulas like Rugiet Ready.*

Oxytocin: Why So Appealing?

Oxytocin is a neuropeptide hormone produced in the hypothalamus. It plays well-documented roles in childbirth, lactation, and social bonding. Research in the 1980s demonstrated that oxytocin could induce penile erections in rats when administered directly to the brain. These early studies generated significant interest in translating these findings to human ED treatment.

The concept makes intuitive sense. Sexual function involves both physical and psychological components. If oxytocin could enhance emotional connection and reduce anxiety while supporting erectile function, it would theoretically address multiple aspects of sexual performance simultaneously. However, theoretical appeal doesn’t always translate to clinical reality.

The Translation Gap: What Works in Rats Doesn’t Work in Humans

Early animal studies showed promise, but decades of human research reveal a different reality. A comprehensive 2021 review examining oxytocin’s effects on sexual function concluded that “the results of these studies do not appear to confirm the facilitatory role of oxytocin found in male and female sexual behavior in animals, both in men and women.” The review’s final remarks note that despite the theoretical mechanisms, exogenous oxytocin administration appears unable to significantly affect human sexual behavior or erectile function.

Interestingly, BlueChew cites this same study in their materials, referencing language about oxytocin’s role in “reducing stress, enhancing emotional safety, and supporting sexual responsiveness”—the claims emphasized in their marketing about “bonding, trust, and emotional safety.” While this language does appear in the study’s discussion of theoretical mechanisms, the study’s evidence-based conclusion states the opposite: that human trials “do not appear to confirm the facilitatory role of oxytocin in human sexual behavior.”

The review acknowledges fundamental reproducibility issues even for these emotional claims, stating that the supposed involvement of oxytocin in social interactions like empathy and trust has been difficult to reproduce. Citing a study’s mechanistic theory while its actual findings show a lack of human efficacy and reproducibility problems is a bit of a red flag (at least a yellow one). A theory is a theory, but the proof is in the numbers.

The Bioavailability Problem

Part of the problem in translating oxytocin’s effects from rats to humans may be the difficulty in finding an adequate delivery method. A pharmacokinetic study specifically examining sublingual (under the tongue) oxytocin delivery in male volunteers tested a 400 IU dose and found extraordinarily poor bioavailability, ranging from 0.007% to 0.07% with significant individual variation. This means virtually none of the administered dose reaches the bloodstream, and what does is unpredictable.*

BlueChew Gold contains 160–240 IU of oxytocin (depending on strength). Using the sublingual bioavailability data (0.007–0.07%), only about 0.011–0.168 IU would theoretically be absorbed across all strength options.

Other clinical trials testing oxytocin for sexual dysfunction used 32 IU doses administered intranasally (in the nose), which has better absorption than sublingual delivery (commonly cited at about 11%). That means about 3.5 IU would make it to the bloodstream. Even those studies also showed no advantage over a placebo! To put that in perspective, BlueChew would need at least 5,000IU of oxytocin to deliver this concentration, and it still would likely be ineffective.*

Apomorphine: Not Without Controversy

Complete transparency requires acknowledging that apomorphine, an ingredient in both Rugiet Ready and BlueChew Gold, also has a complicated history worth understanding. Apomorphine is FDA-approved for Parkinson’s disease (as Apokyn and Onapgo), but the FDA specifically rejected it for erectile dysfunction treatment in the United States.* Both formulations use apomorphine off-label for ED, a legal practice when prescribed by physicians, but an important distinction from FDA-approved ED treatments.

The FDA rejected apomorphine as a standalone ED treatment because safe doses weren’t effective enough, and effective doses had too many side effects. With better options already on the market that offered superior efficacy with fewer side effects, the risk-benefit analysis didn’t justify approval. It was briefly approved in Europe but eventually withdrawn from those markets.

The key distinction: Apomorphine showed modest efficacy in clinical trials with over 5,000 men, but wasn’t good enough as a standalone treatment.* Oxytocin, in contrast, lacks convincing efficacy data for ED in the first place—before even considering its absorption problems or how it compares to alternatives.

Comparing the Formulations: Rugiet Ready vs. BlueChew Gold

Rugiet Ready pioneered the 3-in-1 sublingual ED formulation in 2019, establishing the category standard. The formula combines sildenafil, tadalafil, and apomorphine in a slow-dissolving troche designed for sublingual delivery.*

BlueChew Gold uses a similar foundational approach, combining sildenafil, tadalafil, and apomorphine in sublingual form. The key difference: oxytocin as a fourth ingredient. This product also marks BlueChew’s shift from its original chewable tablets to sublingual delivery.

*Pricing may vary based on subscription and strength selected

Making an Informed Decision

Rugiet

Ready

5 stars

SHOP NOW — $7.29

SHOP NOW — $7.29

When evaluating ED treatments that combine multiple ingredients, the fundamental question isn’t what sounds appealing—it’s what the evidence actually shows. The research on oxytocin is clear: promising in rats, disappointing in humans, and poorly absorbed when taken sublingually.

While the two products are similar, you get some distinct advantages with Rugiet. The Rugiet Ready consultation process includes evaluation by a board-certified physician who reviews your medical questionnaire within 24–48 hours, with ID verification required before any prescription is issued. If approved, physicians customize your formula and dosage based on your specific needs.

Unlimited follow-up messaging with your physician is included, allowing for dose adjustments and ongoing medical oversight.

Ready to find your fix?

**Individual results may vary. Rugiet Ready is a compounded medication. Compounded medications are not FDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs. Compounded drugs are permitted under federal law but only when prescribed by a licensed medical provider and prepared by a licensed compounding pharmacy.

Not for use by individuals under 18 years of age. Consult a licensed healthcare provider before use. Do not take if you are taking nitrates or guanylate cyclase stimulators for pulmonary hypertension. May cause side effects including headache, flushing, indigestion, nasal congestion, dizziness, or nausea. Seek immediate medical attention if you experience an erection lasting more than 4 hours, sudden vision or hearing loss, or signs of an allergic reaction.

This article is for informational purposes only and does not constitute medical advice. Statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider regarding your specific medical condition and treatment options.

Abby Davis